ArticleBehavioural brain research2011
The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.
Article in Behavioural brain research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.Psychopharmacology · 2012Trial
- Theobromine prevents affective symptoms of nicotine withdrawal by modulating the neuroendocrine and immune systems, as well as the glutathione mechanism in the hippocampus.IBRO neuroscience reports · 2025Article
- Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.Physiology & behavior · 2024Review
- Rodent models for nicotine withdrawal.Journal of psychopharmacology (Oxford, England) · 2021Review
- Genetic Differences in Dorsal Hippocampus Acetylcholinesterase Activity Predict Contextual Fear Learning Across Inbred Mouse Strains.Frontiers in psychiatry · 2021Article
- Galantamine as a Treatment Option for Nicotine Addiction.Journal of smoking cessation · 2021Review
- Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.Neuropharmacology · 2020Review
- Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse.Molecular neuropsychiatry · 2019Review
- Cholinergic regulation of fear learning and extinction.Journal of neuroscience research · 2017Review
- Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.Translational psychiatry · 2016Article
- Negative affective states and cognitive impairments in nicotine dependence.Neuroscience and biobehavioral reviews · 2015Review
- New mechanisms and perspectives in nicotine withdrawal.Neuropharmacology · 2015Review
- ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.Behavioural pharmacology · 2015Article
- Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice.Behavioral neuroscience · 2014Article
- Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.Addiction biology · 2014Article
- Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Expert opinion on drug discovery · 2014Review
- Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.Neuropharmacology · 2014Review
- Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning.Neurobiology of learning and memory · 2014Review
- Translational research in nicotine dependence.Cold Spring Harbor perspectives in medicine · 2013Review
- Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Current smoking cessation aids are relatively ineffective at maintaining abstinence during withdrawal. Nicotine withdrawal is associated with a variety of symptoms including cognitive deficits and targeting these deficits may be a useful strategy for maintaining abstinence. Galantamine is an acetylcholinesterase inhibitor and allosteric modulator of nicotinic acetylcholine receptors (nAChRs) with cognitive enhancing effects that may alleviate cognitive deficits associated with nicotine withdrawal. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice were examined. An initial acute dose-response experiment revealed that 0.5 and 1mg/kg galantamine had no effect on fear conditioning. To determine if galantamine would reverse nicotine withdrawal-related deficits in contextual fear conditioning, mice were implanted with osmotic mini-pumps that delivered chronic saline or 6.3mg/kg/d nicotine for 12 days and then pumps were removed. Training and testing of fear conditioning occurred 24 and 48 h later, respectively. Nicotine withdrawal disrupted contextual fear conditioning, which was reversed with 1 but not 0.5mg/kg galantamine. Across all conditions in both studies 2mg/kg galantamine led to high levels of freezing that were likely due to nonspecific effects. The ability of galantamine to reverse nicotine withdrawal-deficits in contextual conditioning is likely mediated through enhanced levels of acetylcholine via inhibition of acetylcholinesterase, potentiation of hippocampal α4β2* nAChRs, or both. The present study suggests that acetylcholinesterase inhibitors and/or drugs that act as allosteric modulators of nAChRs might be targets for smoking cessation aids because they may alleviate withdrawal symptoms such as cognitive deficits that can lead to relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.